Durability of benefit after transcatheter tricuspid valve intervention: insights from actigraphy

Abstract

Tricuspid regurgitation (TR) is associated with high mortality, morbidity and reduced physical capacity. This study was designed to examine the long-term impact of transcatheter tricuspid valve intervention (TTVI) on physical activity by using the method of actigraphy.

July 2022 at a glance: focus on prognosis, devices and valvular heart disease

“…The greatest benefits were noticed in patients with a more severe conditions, in whom physical activity was strongly limited at baseline. 32…”

Closing the gap, or the beauty of alleviating our patients' symptoms

“…In this issue of the Journal, Stocker et al 10 . evaluate the potential effect of transcatheter tricuspid valve intervention (TTVI) on activity levels and physical capacity in HF patients with severe TR using activity tracking devices.…”

“…Extra attention deserves the finding of Stocker et al 10 . described after stratifying the patients according to their baseline CPA into a low activity group (<1350 steps per day), a moderate activity group (IQR 1350–4959 steps per day) and a high activity group (>4959 steps per day).…”

“…In this issue of the Journal, Stocker et al . 10 evaluate the potential effect of transcatheter tricuspid valve intervention (TTVI) on activity levels and physical capacity in HF patients with severe TR using activity tracking devices. In this single‐centre trial, 128 patients undergoing TTVI, predominantly tricuspid transcatheter edge‐to‐edge‐repair, were prospectively enrolled, equipped and trained with the usage of wrist activity tracking devices for 1 week before TTVI, and again at 1–6 months and 1 year after TTVI.…”

“…Extra attention deserves the finding of Stocker et al . 10 described after stratifying the patients according to their baseline CPA into a low activity group (<1350 steps per day), a moderate activity group (IQR 1350–4959 steps per day) and a high activity group (>4959 steps per day). Patients classified as low activity group had a higher NYHA class (37% in NYHA class IV vs. 3% in high activity, p < 0.001), showed increased N‐terminal pro‐B‐type natriuretic peptide levels (5193 [2117–8028] vs. 1174 [1134–3185], p < 0.01), had – using the MLHFQ – a higher (higher scores indicating more significant impairment in health‐related QoL) QoL score (41 [33–52] vs. 31 [22–42], p < 0.05) and were at higher operative risk using the EuroSCORE II (5.7 [4.4–8.3] vs. 3.6 [2.2–5.5], p < 0.01).…”